Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
deaths (OS) | 0.75 [0.66, 0.85] | | < 1 | | 49% | 6 studies (6/-) | 100.0 % | low | serious | high | crucial | - |
deaths (OS) (extension) | 0.81 [0.73, 0.91] | | < 1 | | 0% | 2 studies (2/-) | 100.0 % | low | not evaluable | high | important | - |
progression or deaths (PFS) | 0.81 [0.70, 0.93] | | < 1 | | 68% | 5 studies (5/-) | 99.8 % | low | serious | high | important | - |
DCR | 1.44 [0.95, 2.19] | | > 1 | | 0% | 1 study (1/-) | 95.8 % | NA | not evaluable | | non important | - |
objective responses (ORR) | 2.82 [2.02, 3.93] | | > 1 | | 0% | 3 studies (3/-) | 100.0 % | some concern | not evaluable | moderate | non important | - |
safety endpoints 00 |
AE (any grade) | 1.23 [0.65, 2.32] | | < 1 | | 63% | 5 studies (5/-) | 25.9 % | low | not evaluable | high | non important | - |
AE (grade 3-4) | 1.30 [0.92, 1.86] | | < 1 | | 81% | 5 studies (5/-) | 7.0 % | low | not evaluable | high | non important | - |
AE leading to death (grade 5) | 1.03 [0.69, 1.54] | | < 1 | | 0% | 5 studies (5/-) | 44.9 % | low | not evaluable | high | non important | - |
AE leading to treatment discontinuation (any grade) | 1.59 [1.01, 2.49] | | < 1 | | 72% | 5 studies (5/-) | 2.2 % | low | not evaluable | high | non important | - |
AE leading to treatment discontinuation (grade 3-4) | 3.04 [1.32, 6.97] | | < 1 | | 0% | 1 study (1/-) | 0.4 % | NA | not evaluable | | non important | - |
SAE (any grade) | 1.38 [0.92, 2.07] | | < 1 | | 0% | 1 study (1/-) | 6.1 % | NA | not evaluable | | non important | - |
STRAE (grade 3-4) | 0.30 [0.22, 0.41] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
TRAE (any grade) | 1.66 [1.09, 2.51] | | < 1 | | 0% | 1 study (1/-) | 0.9 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) | 2.77 [1.36, 5.65] | | < 1 | | 0% | 1 study (1/-) | 0.3 % | NA | not evaluable | | non important | - |
TRAE leading to death (grade 5) | 0.96 [0.03, 28.81] | | < 1 | | 0% | 1 study (1/-) | 50.9 % | NA | not evaluable | | non important | - |
TRAE leading to discontinuation (any grade) | 0.53 [0.28, 1.00] | | < 1 | | 0% | 1 study (1/-) | 97.5 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) endpoints 00 |
Abdominal pain TRAE (grade 3-4) | 0.48 [0.01, 24.29] | | < 1 | | 0% | 1 study (1/-) | 64.1 % | NA | not evaluable | | non important | - |
Adrenal insufficiency TRAE (grade 3-4) | 0.48 [0.01, 24.29] | | < 1 | | 0% | 1 study (1/-) | 64.1 % | NA | not evaluable | | non important | - |
Alopecia TRAE (grade 3-4) | 0.48 [0.01, 24.29] | | < 1 | | 0% | 1 study (1/-) | 64.1 % | NA | not evaluable | | non important | - |
Anaemia TRAE (grade 3-4) | 0.24 [0.02, 2.64] | | < 1 | | 0% | 1 study (1/-) | 87.7 % | NA | not evaluable | | non important | - |
Arthralgia TRAE (grade 3-4) | 0.48 [0.01, 24.29] | | < 1 | | 0% | 1 study (1/-) | 64.1 % | NA | not evaluable | | non important | - |
Asthenia TRAE (grade 3-4) | 0.48 [0.01, 24.29] | | < 1 | | 0% | 1 study (1/-) | 64.1 % | NA | not evaluable | | non important | - |
Colitis TRAE (grade 3-4) | 1.93 [0.09, 43.05] | | < 1 | | 0% | 1 study (1/-) | 34.1 % | NA | not evaluable | | non important | - |
Constipation TRAE (grade 3-4) | 0.48 [0.01, 24.29] | | < 1 | | 0% | 1 study (1/-) | 64.1 % | NA | not evaluable | | non important | - |
Cough TRAE (grade 3-4) | 0.48 [0.01, 24.29] | | < 1 | | 0% | 1 study (1/-) | 64.1 % | NA | not evaluable | | non important | - |
Decreased appetite TRAE (grade 3-4) | 2.90 [0.14, 58.35] | | < 1 | | 0% | 1 study (1/-) | 24.6 % | NA | not evaluable | | non important | - |
Diabetes TRAE (grade 3-4) | 0.48 [0.03, 7.71] | | < 1 | | 0% | 1 study (1/-) | 69.7 % | NA | not evaluable | | non important | - |
Diarrhoea TRAE (grade 3-4) | 0.96 [0.09, 10.69] | | < 1 | | 0% | 1 study (1/-) | 51.3 % | NA | not evaluable | | non important | - |
Dry skin TRAE (grade 3-4) | 0.48 [0.01, 24.29] | | < 1 | | 0% | 1 study (1/-) | 64.1 % | NA | not evaluable | | non important | - |
Dysgeusia TRAE (grade 3-4) | 0.48 [0.01, 24.29] | | < 1 | | 0% | 1 study (1/-) | 64.1 % | NA | not evaluable | | non important | - |
Dyspepsia TRAE (grade 3-4) | 0.48 [0.01, 24.29] | | < 1 | | 0% | 1 study (1/-) | 64.1 % | NA | not evaluable | | non important | - |
Dyspnoea TRAE (grade 3-4) | 0.48 [0.01, 24.29] | | < 1 | | 0% | 1 study (1/-) | 64.1 % | NA | not evaluable | | non important | - |
Eczema TRAE (grade 3-4) | 0.48 [0.01, 24.29] | | < 1 | | 0% | 1 study (1/-) | 64.1 % | NA | not evaluable | | non important | - |
Fatigue TRAE (grade 3-4) | 1.45 [0.15, 14.03] | | < 1 | | 0% | 1 study (1/-) | 37.6 % | NA | not evaluable | | non important | - |
Headache TRAE (grade 3-4) | 0.48 [0.01, 24.29] | | < 1 | | 0% | 1 study (1/-) | 64.1 % | NA | not evaluable | | non important | - |
Hepatitis TRAE (grade 3-4) | 3.88 [0.20, 74.00] | | < 1 | | 0% | 1 study (1/-) | 18.6 % | NA | not evaluable | | non important | - |
Hyperthyroidism TRAE (grade 3-4) | 0.48 [0.01, 24.29] | | < 1 | | 0% | 1 study (1/-) | 64.1 % | NA | not evaluable | | non important | - |
Hypophysitis TRAE (grade 3-4) | 0.96 [0.03, 28.81] | | < 1 | | 0% | 1 study (1/-) | 50.9 % | NA | not evaluable | | non important | - |
Hypothyroidism TRAE (grade 3-4) | 0.96 [0.03, 28.81] | | < 1 | | 0% | 1 study (1/-) | 50.9 % | NA | not evaluable | | non important | - |
Increase AST TRAE (grade 3-4) | 3.75 [0.85, 16.64] | | < 1 | | 0% | 1 study (1/-) | 4.2 % | NA | not evaluable | | non important | - |
Increased ALT TRAE (grade 3-4) | 2.45 [0.53, 11.36] | | < 1 | | 0% | 1 study (1/-) | 12.6 % | NA | not evaluable | | non important | - |
Infusion-related reactions TRAE (grade 3-4) | 0.48 [0.01, 24.29] | | < 1 | | 0% | 1 study (1/-) | 64.1 % | NA | not evaluable | | non important | - |
Leucopenia TRAE (grade 3-4) | 0.24 [0.01, 7.16] | | < 1 | | 0% | 1 study (1/-) | 79.2 % | NA | not evaluable | | non important | - |
Maculopapular rash TRAE (grade 3-4) | 0.48 [0.01, 24.29] | | < 1 | | 0% | 1 study (1/-) | 64.1 % | NA | not evaluable | | non important | - |
Myalgia TRAE (grade 3-4) | 0.48 [0.01, 24.29] | | < 1 | | 0% | 1 study (1/-) | 64.1 % | NA | not evaluable | | non important | - |
Myositis TRAE (grade 3-4) | 0.96 [0.03, 28.81] | | < 1 | | 0% | 1 study (1/-) | 50.9 % | NA | not evaluable | | non important | - |
Nausea TRAE (grade 3-4) | 0.48 [0.01, 24.29] | | < 1 | | 0% | 1 study (1/-) | 64.1 % | NA | not evaluable | | non important | - |
Palmar-plantar erythrodysaesthesia syndrome TRAE (grade 3-4) | 0.96 [0.03, 28.81] | | < 1 | | 0% | 1 study (1/-) | 50.9 % | NA | not evaluable | | non important | - |
Peripheral oedema TRAE (grade 3-4) | 0.48 [0.01, 24.29] | | < 1 | | 0% | 1 study (1/-) | 64.1 % | NA | not evaluable | | non important | - |
Pneumonitis TRAE (grade 3-4) | 1.93 [0.09, 43.05] | | < 1 | | 0% | 1 study (1/-) | 34.1 % | NA | not evaluable | | non important | - |
Pruritus TRAE (grade 3-4) | 0.96 [0.03, 28.81] | | < 1 | | 0% | 1 study (1/-) | 50.9 % | NA | not evaluable | | non important | - |
Pyrexia TRAE (grade 3-4) | 0.48 [0.01, 24.29] | | < 1 | | 0% | 1 study (1/-) | 64.1 % | NA | not evaluable | | non important | - |
Rash TRAE (grade 3-4) | 0.96 [0.03, 28.81] | | < 1 | | 0% | 1 study (1/-) | 50.9 % | NA | not evaluable | | non important | - |
Severe skin reaction TRAE (grade 3-4) | 5.87 [0.33, 105.85] | | < 1 | | 0% | 1 study (1/-) | 11.8 % | NA | not evaluable | | non important | - |
Stomatitis TRAE (grade 3-4) | 0.48 [0.01, 24.29] | | < 1 | | 0% | 1 study (1/-) | 64.1 % | NA | not evaluable | | non important | - |
Thrombocytopenia TRAE (grade 3-4) | 0.48 [0.01, 24.29] | | < 1 | | 0% | 1 study (1/-) | 64.1 % | NA | not evaluable | | non important | - |
Thyroiditis TRAE (grade 3-4) | 0.48 [0.01, 24.29] | | < 1 | | 0% | 1 study (1/-) | 64.1 % | NA | not evaluable | | non important | - |
Vomiting TRAE (grade 3-4) | 0.48 [0.01, 24.29] | | < 1 | | 0% | 1 study (1/-) | 64.1 % | NA | not evaluable | | non important | - |
Weight decreased TRAE (grade 3-4) | 0.96 [0.03, 28.81] | | < 1 | | 0% | 1 study (1/-) | 50.9 % | NA | not evaluable | | non important | - |
AE (grade 3-4) endpoints 00 |
Abdominal pain AE (grade 3-4) | 0.89 [0.13, 6.01] | | < 1 | | 38% | 2 studies (2/-) | 54.7 % | some concern | not evaluable | moderate | non important | - |
Acute kidney injury AE (grade 3-4) | 0.16 [0.02, 1.51] | | < 1 | | 0% | 1 study (1/-) | 94.5 % | NA | not evaluable | | non important | - |
Alopecia AE (grade 3-4) | 0.47 [0.01, 23.97] | | < 1 | | 0% | 1 study (1/-) | 64.3 % | NA | not evaluable | | non important | - |
Anaemia AE (grade 3-4) | 0.61 [0.25, 1.49] | | < 1 | | 37% | 2 studies (2/-) | 86.2 % | low | not evaluable | high | non important | - |
Arthralgia AE (grade 3-4) | 0.48 [0.03, 7.71] | | < 1 | | 0% | 1 study (1/-) | 69.7 % | NA | not evaluable | | non important | - |
Asthenia AE (grade 3-4) | 0.16 [0.02, 1.11] | | < 1 | | 0% | 2 studies (2/-) | 96.8 % | some concern | not evaluable | moderate | non important | - |
Back pain AE (grade 3-4) | 3.88 [0.20, 74.00] | | < 1 | | 0% | 1 study (1/-) | 18.6 % | NA | not evaluable | | non important | - |
Constipation AE (grade 3-4) | 0.71 [0.05, 9.27] | | < 1 | | 0% | 2 studies (2/-) | 60.3 % | low | not evaluable | high | non important | - |
Cough AE (grade 3-4) | 0.32 [0.02, 4.18] | | < 1 | | 0% | 2 studies (2/-) | 80.6 % | some concern | not evaluable | moderate | non important | - |
Decreased appetite AE (grade 3-4) | 0.62 [0.08, 4.71] | | < 1 | | 45% | 2 studies (2/-) | 67.9 % | some concern | not evaluable | moderate | non important | - |
Diarrhoea AE (grade 3-4) | 0.42 [0.18, 1.02] | | < 1 | | 0% | 2 studies (2/-) | 97.3 % | some concern | not evaluable | moderate | non important | - |
Dyspepsia AE (grade 3-4) | 0.12 [0.01, 2.61] | | < 1 | | 0% | 1 study (1/-) | 90.9 % | NA | not evaluable | | non important | - |
Dyspnoea AE (grade 3-4) | 0.46 [0.12, 1.77] | | < 1 | | 0% | 2 studies (2/-) | 87.1 % | some concern | not evaluable | moderate | non important | - |
Epistaxis AE (grade 3-4) | 0.24 [0.01, 7.07] | | < 1 | | 0% | 1 study (1/-) | 79.4 % | NA | not evaluable | | non important | - |
Fatigue AE (grade 3-4) | 0.99 [0.39, 2.49] | | < 1 | | 0% | 2 studies (2/-) | 50.7 % | some concern | not evaluable | moderate | non important | - |
Hypertension AE (grade 3-4) | 1.29 [0.73, 2.28] | | < 1 | | 0% | 1 study (1/-) | 18.8 % | NA | not evaluable | | non important | - |
Increase AST AE (grade 3-4) | 1.66 [0.96, 2.86] | | < 1 | | 0% | 2 studies (2/-) | 3.6 % | low | not evaluable | high | non important | - |
Increased ALT AE (grade 3-4) | 2.36 [0.97, 5.77] | | < 1 | | 0% | 2 studies (2/-) | 3.0 % | low | not evaluable | high | non important | - |
Infusion-related reaction AE (grade 3-4) | 7.75 [0.44, 135.83] | | < 1 | | 0% | 1 study (1/-) | 8.3 % | NA | not evaluable | | non important | - |
Nausea AE (grade 3-4) | 0.71 [0.11, 4.37] | | < 1 | | 0% | 2 studies (2/-) | 64.4 % | low | not evaluable | high | non important | - |
Palmar–plantar erythrodysesthesia syndrome AE (grade 3-4) | 0.02 [0.00, 0.28] | | < 1 | | 0% | 1 study (1/-) | 99.7 % | NA | not evaluable | | non important | - |
Peripheral oedema AE (grade 3-4) | 0.48 [0.01, 24.29] | | < 1 | | 0% | 1 study (1/-) | 64.1 % | NA | not evaluable | | non important | - |
Proteinuria AE (grade 3-4) | 4.86 [0.62, 38.30] | | < 1 | | 0% | 1 study (1/-) | 6.8 % | NA | not evaluable | | non important | - |
Pruritus AE (grade 3-4) | 0.71 [0.05, 9.27] | | < 1 | | 0% | 2 studies (2/-) | 60.3 % | low | not evaluable | high | non important | - |
Pyrexia AE (grade 3-4) | 1.12 [0.25, 4.99] | | < 1 | | 0% | 2 studies (2/-) | 44.2 % | some concern | not evaluable | moderate | non important | - |
Rash AE (grade 3-4) | 0.32 [0.01, 10.00] | | < 1 | | 61% | 2 studies (2/-) | 73.8 % | some concern | not evaluable | moderate | non important | - |
Thrombocytopenia AE (grade 3-4) | 0.95 [0.23, 3.84] | | < 1 | | 0% | 1 study (1/-) | 53.0 % | NA | not evaluable | | non important | - |
Vomiting AE (grade 3-4) | 0.95 [0.09, 10.54] | | < 1 | | 0% | 1 study (1/-) | 51.7 % | NA | not evaluable | | non important | - |
Weight decreased AE (grade 3-4) | 0.24 [0.01, 7.07] | | < 1 | | 0% | 1 study (1/-) | 79.4 % | NA | not evaluable | | non important | - |